What is the current stock price of Eledon Pharmaceuticals, Inc. (ELDN)?

As of the latest market data, Eledon Pharmaceuticals, Inc. (ELDN) is trading at $3.98. The stock has seen a gain of 6.70% today.

Does Eledon Pharmaceuticals, Inc. (ELDN) pay a dividend?

Based on current data, Eledon Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Eledon Pharmaceuticals, Inc.?

The current market capitalization of Eledon Pharmaceuticals, Inc. (ELDN) is approximately unavailable.

ELDN

Eledon Pharmaceuticals, Inc.·Healthcare

3.98

6.702%(+0.25)

Market Closed

4.15

4.271%(+0.17)

After Hours

Last Updated: — ET

52W L: $1.3552W H: $4.60

ELDN NEWS

defenseworld.net

Mar 30

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy

globenewswire.com

Mar 19

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation IRVINE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights.

seekingalpha.com

Mar 16

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Eledon Pharmaceuticals remains a "Strong Buy" following positive phase 2 BESTOW results for tegoprubart in kidney transplant rejection prevention. Company's tegoprubart demonstrated non-inferiority to tacrolimus and enabled insulin independence in 10/12 T1D islet transplant patients, with no toxic adverse events. Multiple Orphan Drug Designations and upcoming regulatory meetings in 2026 position ELDN for key catalysts and expanded transplant indications.

globenewswire.com

Mar 10

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation.

prnewswire.com

Mar 9

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine.

globenewswire.com

Mar 4

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Company Profile

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2014-09-17

Beta

0.84

Websiteeledon.com↗